16-30 of 62
Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia
MinuteCE®Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Bernhard Hellmich, MD
Andreas Kronbichler, MD
Silke R. Brix, MD, MRCP, SCPR
Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor
MinuteCE®Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor
Seema A. Bhat, MD
Jeremy S. Abramson, MD, MMSc
Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies
MinuteCE®Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies
Seema A. Bhat, MD
Jeremy S. Abramson, MD, MMSc
Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy
MinuteCE®Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy
Seema A. Bhat, MD
Jeremy S. Abramson, MD, MMSc
Emerging data with potentially guideline-changing implications in CLL/SLL and MCL
MinuteCE®Emerging data with potentially guideline-changing implications in CLL/SLL and MCL
Seema A. Bhat, MD
Jeremy S. Abramson, MD, MMSc
- advertisement
Ignacio Duran, MD
Wenxin Xu, MD
Sandy Srinivas, MD
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Ignacio Duran, MD
Wenxin Xu, MD
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Ignacio Duran, MD
Sandy Srinivas, MD
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
MinuteCE®Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Ignacio Duran, MD
Sandy Srinivas, MD
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
MinuteCE®Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Wenxin Xu, MD
Sandy Srinivas, MD
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
MinuteCE®Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Wenxin Xu, MD
Sandy Srinivas, MD
- advertisement
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Wenxin Xu, MD
Sandy Srinivas, MD
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
MinuteCE®Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Ignacio Duran, MD
Wenxin Xu, MD
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®Emerging targeted therapy combination strategies in genitourinary malignancies
Ignacio Duran, MD
